Recommended Free Tools
CDX2 is a protein that helps identify intestinal differentiation in tumor cells. A positive nuclear stain can support a colorectal origin, especially when it appears with a characteristic set of other markers, but it cannot prove by itself where a cancer began. Some non-colorectal tumors express CDX2, and some colorectal cancers do not.
What a CDX2 stain tells a pathologist
CDX2 is a transcription factor associated with intestinal epithelial differentiation. In immunohistochemistry (IHC), a laboratory applies an antibody to a tissue sample to see whether tumor cells contain the protein. CDX2 staining is assessed in the cell nucleus. When tumor nuclei stain positive, the finding supports an intestinal-type differentiation program.
As an Amazon Associate I earn from qualifying purchases.
That is useful when a biopsy shows an adenocarcinoma but its site of origin is uncertain—for example, when a tumor is found in the liver or another site away from the bowel. A positive result can make an intestinal source more plausible, including colorectal cancer. But differentiation is not the same as location: CDX2 indicates what kind of cellular program the tumor resembles, not the organ in which it necessarily started.
In practical terms, the stain answers a narrower question than “Where did this cancer begin?” It provides evidence about the tumor cells’ characteristics. A pathologist then weighs that evidence with the microscopic appearance, the biopsy site, other stains, prior pathology samples, imaging findings, and clinical history. If the tumor is metastatic, these clues are particularly important because the sampled tissue may be far from the primary cancer.
Pathologists therefore interpret CDX2 alongside the tumor’s microscopic appearance, other IHC markers, prior pathology samples, imaging findings, and the patient’s clinical history. The result is one part of a site-of-origin assessment, not a stand-alone diagnostic test.
The common colorectal marker pattern
A typical colorectal adenocarcinoma profile is CK7-negative, CK20-positive, and CDX2-positive. CK7 and CK20 are cytokeratins—proteins used as markers of epithelial cell patterns. In combination, the three stains provide a broader pattern than CDX2 alone. “Negative” and “positive” describe staining results in the tumor cells; a pathologist interprets them as a profile rather than as a simple checklist.
The European Society for Medical Oncology’s 2023 clinical practice guideline on cancer of unknown primary says that at least 80% of colorectal cancers show the classic CK7−/CK20+/CDX2+ immunophenotype, with CK20 and CDX2 staining usually diffuse and strong. This is a common pattern, not a requirement: a colorectal tumor may not show every feature, and other tumor types can overlap with it.
Free tools Windows power users keep installed
One-click scans. No signup required.
For liver biopsies showing adenocarcinoma, that ESMO guideline recommends CK7, CK20, CDX2, and TTF1 as an initial IHC panel, with additional markers chosen for the clinical context. TTF1 is included because the pathologist is considering more than one possible origin. The panel is a starting point for a particular diagnostic setting, not a universal fixed recipe for every tumor.
The CSCO colorectal cancer guideline update likewise describes CK7-negative/CK20-positive/CDX2-positive as the typical colorectal adenocarcinoma immunophenotype and advises choosing markers according to the differential diagnosis. The pattern is useful because several findings point in the same direction; its value does not depend on CDX2 being uniquely colorectal.
Rank #2
Why CDX2 is not specific to colorectal cancer
CDX2 is strongly associated with intestinal differentiation, but it is not exclusive to colorectal tumors. Gastric and gastroesophageal cancers, pancreatic and biliary tumors, mucinous ovarian tumors, and bladder adenocarcinomas can also express it. Expression may vary between tumor types and may be present in only some tumor cells.
A 2003 immunohistochemical survey of 476 primary and metastatic carcinomas found CDX2 expression in all but one of the evaluated colorectal and duodenal tumors. It also found high-level expression in mucinous ovarian and bladder adenocarcinomas, and variable expression in gastric, gastroesophageal, pancreatic, and biliary tumors. The survey’s authors described uniform expression as highly, but incompletely, specific for intestinal adenocarcinoma. The important distinction is that a strong association can make a stain useful without making it exclusive.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →A separate 2003 tissue-microarray survey of 745 cancers reported strong, extensive staining in 90% of colonic adenocarcinomas. Extensive staining was also observed in 20–30% of stomach, esophageal, and selected ovarian carcinomas. These findings reinforce both sides of the interpretation: extensive CDX2 staining is common in colonic tumors, but it can occur in other tumor groups as well. The rates belong to that survey and should not be treated as universal estimates.
One 2012 study illustrates how much CDX2 expression differed among the tumor groups it tested:
| Tumor group in the study | CDX2-positive cases | What the figure describes |
|---|---|---|
| Colorectal adenocarcinoma | 114 of 118 (97%) | Expression in the colorectal cohort |
| Gastric adenocarcinoma | 36 of 59 (61%) | Expression in the gastric cohort |
| Pancreatic adenocarcinoma | 5 of 32 (16%) | Expression in the pancreatic cohort |
These are results from Bayrak and colleagues’ 2012 comparison, not universal rates for every laboratory or patient. Studies can differ in the tumors included, staining methods, antibodies, and thresholds for calling a result positive. The figures show why a CDX2-positive result can support colorectal origin while still leaving other possibilities open.
In that 2012 comparison, the CK7-negative/CK20-positive pattern was less sensitive but more specific for colorectal origin than CDX2 alone. Put simply, CDX2 identified more colorectal cases in that cohort, while the combined cytokeratin pattern was more discriminating among the tumors tested. That trade-off is one reason pathologists consider marker patterns rather than asking whether a single stain is simply “positive.”
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How other stains can sharpen the interpretation
Pathologists choose companion markers to test whether the overall staining pattern fits the leading possibilities. CK7 and CK20 help characterize the pattern; TTF1 or other markers may be selected when the differential diagnosis includes tumors from other sites. The appropriate panel depends on what the tissue looks like and which origins are clinically plausible.
SATB2 is another marker that can add evidence for colorectal differentiation in suitable settings. It is not a substitute for interpreting the whole case: its value depends on the tumor types being compared, and no marker combination eliminates every overlap.
Li and colleagues’ 2018 study compared marker strategies in a defined set of 222 colorectal cancers and 375 other carcinomas. The reported sensitivity is the proportion of colorectal cancers in that set identified as positive by the marker strategy; specificity is the proportion of the comparison tumors identified as negative. The results were:
| Marker strategy | Sensitivity | Specificity |
|---|---|---|
| CDX2 alone | 99% | 85% |
| CDX2 and CK20 | 92% | 93% |
| SATB2 and CK20 | 90% | 98% |
In that study set, pairing markers changed the balance between sensitivity and specificity: the SATB2/CK20 combination had higher specificity than CDX2 alone, while its reported sensitivity was lower. These figures should not be treated as a head-to-head prediction for an individual patient or as performance guarantees across laboratories. The comparison tumors and study methods affect the estimates.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsThe 2018 study also found that SATB2 combinations with CK20 or villin were more specific than the corresponding CDX2 dual stains at broadly comparable sensitivity in its tested set. That supports SATB2 as a potentially useful companion in selected differentials, not as a universal protocol or a result that settles the diagnosis by itself.
Sensitivity and specificity describe performance in a particular study group; they do not tell an individual patient the probability that a tumor began in the colon. That probability also depends on which alternative tumor types are realistic in the case and on the clinical and imaging findings. The numbers from the 2012 and 2018 studies also should not be compared as though the studies tested the same tumors under the same conditions.
Why clinical history and tumor appearance still matter
Even a set of stains that strongly resembles colorectal cancer may be shared by a competing tumor. A 2024 study examined 269 colorectal cancers using CDX2 and SATB2 phenotypes and found that loss of one or both markers was associated with poorly differentiated histotypes, mucus production, and mismatch-repair-deficient phenotypes. In the same study’s assessment of 684 other tumors, investigators could not distinguish one ovarian mucinous cystadenocarcinoma with a CK7-negative/CK20-positive/CDX2-positive/SATB2-positive profile from metastatic colorectal cancer without the patient’s history and clinical information.
This example shows why a marker panel is interpreted in context. The pathologist considers whether the tissue’s architecture and cell features fit the proposed origin, whether an earlier tumor is available for comparison, and whether imaging and clinical history support that site. If a patient has a known prior colorectal cancer, comparing the new sample with the earlier specimen may be informative. Conversely, a possible primary ovarian mucinous tumor can require careful correlation because its markers may overlap with a colorectal metastasis.
The CSCO colorectal cancer guideline update describes CK7-negative/CK20-positive/CDX2-positive as the typical colorectal adenocarcinoma immunophenotype and advises selecting markers appropriately for the differential diagnosis. “Typical” describes a pattern that is often useful; it does not mean every colorectal tumor has it or that no other tumor can resemble it.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What a negative CDX2 result means
A negative CDX2 stain does not rule out colorectal cancer. Some colorectal tumors lose CDX2 expression, and the 2024 study linked loss of CDX2 and/or SATB2 with particular tumor features, including poor differentiation and mismatch-repair-deficient phenotypes. Thus, the absence of staining is evidence to interpret, not a final exclusion.
When CDX2 is negative, the remaining tissue findings and other markers still matter. A pathologist may weigh the tumor’s morphology, CK7 and CK20 pattern, additional stains chosen for the differential, comparison with previous specimens, and clinical information. The meaning of a negative result depends on the complete pattern and the question being investigated.
Likewise, the reported high sensitivity of CDX2 in some colorectal cohorts should not be confused with a guarantee that every colorectal cancer stains. A result may be less informative in a poorly differentiated tumor or in a tumor with a mismatch-repair-deficient phenotype, where loss of CDX2 and/or SATB2 may occur. The complete pathology assessment remains important when the stain is absent.
How to understand CDX2 in a pathology work-up
- Start with the tumor type and location. The pathologist establishes what the biopsy looks like and whether the primary site is known or uncertain.
- Read CDX2 as evidence of differentiation. Nuclear positivity supports an intestinal-type program; it does not independently identify the organ of origin.
- Look at the accompanying pattern. CK7, CK20, and, where appropriate, TTF1, SATB2, or other markers help assess competing origins.
- Reconcile stains with the case. Morphology, prior samples, imaging, and clinical history may support or challenge a proposed colorectal origin.
- Interpret negative findings in context. A negative CDX2 result cannot by itself exclude colorectal cancer, just as a positive result cannot by itself prove it.
In short, CDX2 helps distinguish colorectal cancer by providing evidence of intestinal differentiation and by contributing to a recognizable marker pattern. The most reliable site assignment comes from the combined pathology and clinical assessment, especially when another tumor type can share the same staining profile.
Frequently Asked Questions
Is CDX2 specific for colorectal cancer?
No. CDX2 is associated with intestinal differentiation and is often positive in colorectal adenocarcinoma, but it can also be expressed by gastric, gastroesophageal, pancreatic, biliary, mucinous ovarian, and bladder adenocarcinomas. A positive stain supports a possibility; it does not establish the primary site by itself.
Can CDX2 be positive in cancers other than colorectal cancer?
Yes. Studies have reported CDX2 expression in several non-colorectal tumor types. In a 2012 cohort, for example, it was positive in 36 of 59 gastric adenocarcinomas and 5 of 32 pancreatic adenocarcinomas. Those are study-specific figures, not universal rates.
Does a negative CDX2 stain rule out colorectal cancer?
No. Some colorectal tumors lose CDX2, including tumors associated with poor differentiation or mismatch-repair-deficient phenotypes. Pathologists interpret a negative result with the tumor’s appearance, other markers, prior specimens, and clinical information.
The Bottom Line
CDX2 is a useful clue to intestinal differentiation, not a stand-alone locator of a tumor’s origin. A colorectal-like CK7/CK20/CDX2 pattern—and sometimes SATB2—can strengthen the case, but other cancers can overlap and some colorectal cancers lack these markers. Pathologists reach the most reliable conclusion by integrating stains with morphology, prior samples, imaging, and clinical history.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
